Equities research analysts expect that Beigene Ltd (NASDAQ:BGNE) will announce earnings of ($3.01) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Beigene’s earnings, with the highest EPS estimate coming in at ($2.50) and the lowest estimate coming in at ($3.39). Beigene posted earnings per share of ($2.92) during the same quarter last year, which suggests a negative year-over-year growth rate of 3.1%. The business is expected to announce its next quarterly earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Beigene will report full-year earnings of ($12.95) per share for the current year, with EPS estimates ranging from ($16.01) to ($9.73). For the next year, analysts forecast that the company will report earnings of ($12.30) per share, with EPS estimates ranging from ($14.78) to ($8.21). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Beigene.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($2.81) earnings per share for the quarter, beating the consensus estimate of ($3.15) by $0.34. The firm had revenue of $77.83 million for the quarter, compared to analyst estimates of $55.79 million. Beigene had a negative return on equity of 44.75% and a negative net margin of 302.58%. Beigene’s quarterly revenue was up 139.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.03) earnings per share.
A number of research analysts have commented on BGNE shares. Zacks Investment Research upgraded Beigene from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Maxim Group set a $170.00 target price on Beigene and gave the company a “buy” rating in a research note on Thursday, February 28th. Sanford C. Bernstein started coverage on Beigene in a research note on Tuesday, June 4th. They issued an “outperform” rating and a $201.00 target price on the stock. Morgan Stanley boosted their target price on Beigene from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, May 14th. Finally, BidaskClub upgraded Beigene from a “sell” rating to a “hold” rating in a research note on Friday, June 21st. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Beigene has an average rating of “Buy” and a consensus price target of $182.28.
In other news, insider Xiaobin Wu sold 5,955 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $124.52, for a total transaction of $741,516.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald W. Glazer sold 15,027 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $125.11, for a total value of $1,880,027.97. Following the sale, the director now owns 3,911,518 shares of the company’s stock, valued at approximately $489,370,016.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,236 shares of company stock valued at $8,286,319. 13.30% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in BGNE. Neuburgh Advisers LLC bought a new stake in shares of Beigene during the 4th quarter worth about $27,000. Advisor Group Inc. boosted its stake in shares of Beigene by 301.4% during the 4th quarter. Advisor Group Inc. now owns 285 shares of the company’s stock worth $40,000 after acquiring an additional 214 shares in the last quarter. PNC Financial Services Group Inc. bought a new stake in shares of Beigene during the 4th quarter worth about $46,000. Quadrant Capital Group LLC boosted its stake in shares of Beigene by 131.8% during the 1st quarter. Quadrant Capital Group LLC now owns 364 shares of the company’s stock worth $47,000 after acquiring an additional 207 shares in the last quarter. Finally, LS Investment Advisors LLC bought a new stake in shares of Beigene during the 4th quarter worth about $71,000.
NASDAQ:BGNE traded up $3.95 during trading hours on Wednesday, hitting $124.97. 6,531 shares of the company’s stock traded hands, compared to its average volume of 318,380. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of -10.29 and a beta of 1.11. Beigene has a twelve month low of $105.19 and a twelve month high of $194.56. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.47 and a current ratio of 7.52. The stock has a fifty day moving average price of $124.42.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Recommended Story: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.